{
  "trial_id": "NCT04725812",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Provision of signed and dated informed consent form",
      "label": "met"
    },
    {
      "criterion": "Stated willingness to comply with all study procedures & availability for study duration",
      "label": "met"
    },
    {
      "criterion": "Biologically female, aged \u226513, body weight \u226540kg",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Known allergic reactions eculizumab or meningococcal vaccine",
      "label": "unknown"
    },
    {
      "criterion": "Febrile illness within prior 2 weeks",
      "label": "not_met"
    }
  ],
  "notes": "The patient has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%. He was treated with plasma exchange and corticosteroids for atypical hemolytic uremic syndrome.",
  "_meta": {
    "topic_id": "68",
    "trial_id": "NCT04725812",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}